Company intelligence / Profile preview

Agile Therapeutics

Princeton, New Jersey, United Statesagiletherapeutics.com ↗

Ownership: Public · AGRX
Employees: ~19
Development stage: Other

Overview

Twirla®, the company’s lead product—a once-weekly combined hormonal contraceptive patch—has completed Phase 3 trials demonstrating safety and efficacy. It was approved by the FDA in February 2020. Post-marketing surveillance has shown a favorable safety profile consistent with clinical trial data. All other pipeline programs are currently on hold as the company focuses on commercializing Twirla.

Therapeutic areas: Women's Health
Modalities: Transdermal patches (hormonal contraceptives)
Industry: Biotech

Partnerships

Integration into Exeltis USA's women's health portfolio after acquisition by Insud Pharma group; no major external pharma partnerships disclosed recently.

Beyond the preview

Go deeper on Agile Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Agile Therapeutics.